R
Richard M. Hoffman
Researcher at Roy J. and Lucille A. Carver College of Medicine
Publications - 210
Citations - 10684
Richard M. Hoffman is an academic researcher from Roy J. and Lucille A. Carver College of Medicine. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 49, co-authored 197 publications receiving 9923 citations. Previous affiliations of Richard M. Hoffman include University of Arizona & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States
B. Al Hussein Al Awamlh,Xian-min Wu,Daniel A. Barocas,Kelvin A. Moses,Richard M. Hoffman,Spyridon P. Basourakos,Patrick Lewicki,Woodson Smelser,Camilo Arenas-Gallo,Jonathan Shoag +9 more
Journal ArticleDOI
PSA Thresholds for Prostate Cancer Detection
TL;DR: It is concluded that "[f]ree serum PSA measurements may reduce the number of additional biopsies required by the lower PSA cutoff" in men with PSAs in the range of 2.6 to 4.0 ng/mL.
Journal ArticleDOI
Vitamin E reduced secondary cardiovascular disease events in patients receiving long-term hemodialysis
TL;DR: Patients with CVD who were stable on hemodialysis and excluded from the study included anticoagulant therapy with warfarin, malignant disease, pregnancy, or treatment with a hypolipemic agent ≤ 8 weeks before study inception.
Journal ArticleDOI
Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS).
Alicia K. Morgans,Kang-Hsien Fan,Tatsuki Koyama,Peter C. Albertsen,Michael Goodman,Ann S. Hamilton,Richard M. Hoffman,Janet L. Stanford,Antoinette M. Stroup,Christina Louise Derleth,David F. Penson +10 more
TL;DR: Men treated with prolonged ADT (>1 yr) reported higher rates of osteoporosis and fracture at 15 year follow up, and half of men treated for >1 yr ADT reported bone medication use.
Journal ArticleDOI
Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality
TL;DR: Screening increased risk for diagnosis of prostate cancer and reduced risk for prostate cancer mortality compared with usual care; groups did not differ for all-cause mortality.